Home



ZADAXIN
(thymosin alpha 1)



ZADAXIN
Bibliography &
Presentations



Medical
Conferences



Contact



Site Map



International
Language Support
   

<< Previous Section Table of Contents Next Section >>

Hepatitis C

Summary and Key Takeaways

Hepatitis C Summary
The United States National Institutes of Health (NIH) Consensus Meeting held in March 1997 reviewed new data in the treatment of CHC. The NIH CHC conference concluded that Zadaxin, when used in combination with IFNα, is “the most promising of the cytokines or immunomodulators tested thus far.” (110)

Key Takeaways
• Zadaxin added to IFN more than doubles the efficacy rate of IFN alone in end-of treatment and sustained response.
• Zadaxin plus IFN is effective in IFN nonresponders and in cases of relapse after IFN treatment.
• Response rates increase during a full 48 weeks of therapy.
• Zadaxin combination therapy has a high response rate even in genotype 1 patients.
• No major toxicity has been observed in patients receiving combination therapy.


  Home | Zadaxin | Scientific Papers | Conferences | Contact | Site Map
Copyright © 2003-2004 SciClone Pharmaceuticals International